You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

 

Online download statistics by month:

Online download statistics by month: October 2020 to June 2025

AbstractFullPdf
Oct 2020356356113
Nov 202010610649
Dec 2020717127
Jan 2021777735
Feb 2021434324
Mar 2021525230
Apr 2021353515
May 2021454544
Jun 2021434331
Jul 2021585834
Aug 2021454526
Sep 2021303020
Oct 2021525254
Nov 2021777744
Dec 2021464626
Jan 2022454724
Feb 2022393923
Mar 2022434329
Apr 2022414327
May 2022505029
Jun 2022495433
Jul 2022313318
Aug 2022444534
Sep 2022404133
Oct 2022525443
Nov 2022393925
Dec 2022333318
Jan 2023363613
Feb 2023586015
Mar 2023505124
Apr 2023191915
May 2023323214
Jun 202321219
Jul 2023202023
Aug 2023333316
Sep 2023323316
Oct 2023343414
Nov 2023363615
Dec 2023363615
Jan 2024303121
Feb 2024464720
Mar 2024505099
Apr 2024242521
May 2024202011
Jun 2024303018
Jul 2024313214
Aug 202423249
Sep 20242424134
Oct 2024262913
Nov 2024474819
Dec 2024585912
Jan 2025696920
Feb 202517517517
Mar 2025444419
Apr 2025606023
May 2025313117
Jun 2025303118
Total286728971602